Allergan Aesthetics (AbbVie) Reports CHMP Positive Opinion for Boey to Temporarily Improve Glabellar Lines in Adults

Why It Matters

The CHMP endorsement positions Boey as a new competitor in the lucrative European aesthetic market, expanding AbbVie’s botulinum toxin portfolio and offering clinicians a faster‑acting option for glabellar line treatment.

Key Takeaways

• CHMP backs Boey for moderate-to-severe glabellar lines across 30 EEA states
• Two Phase III trials met primary and secondary endpoints, showing rapid onset
• Efficacy lasts 2‑3 weeks, with effects starting at 8 hours
• Boey adds to Allergan's botulinum toxin portfolio, targeting European aesthetic market

Pulse Analysis

The European Medicines Agency’s CHMP opinion marks a pivotal regulatory milestone for Boey, a novel botulinum toxin formulation from Allergan Aesthetics. By recommending approval across all 30 EEA countries, the committee signals confidence in the drug’s safety and efficacy profile, accelerating its path to market. This endorsement is especially significant in Europe, where the aesthetic sector accounts for a substantial share of global botulinum toxin sales, and where clinicians often seek products with differentiated onset and duration characteristics.

Clinical data from the two Phase III studies underpin the CHMP’s favorable view. Participants experienced visible wrinkle reduction within eight hours—a faster onset than the industry‑standard onabotulinumtoxinA (Botox) and comparable to the rapid action of abobotulinumtoxinA (Dysport). Moreover, the therapeutic effect persisted for two to three weeks, offering a middle ground between shorter‑acting competitors and longer‑lasting formulations. These performance metrics, combined with a robust safety record, position Boey as a compelling alternative for patients desiring quick results without compromising durability.

Strategically, Boey expands AbbVie’s aesthetic pipeline, diversifying revenue streams beyond its established portfolio. The European market, valued at over $1 billion annually, presents a fertile ground for growth, and a successful launch could set the stage for subsequent regulatory submissions in the United States and other regions. As competition intensifies, Boey’s rapid onset and moderate duration may attract both high‑volume clinics and premium providers, reinforcing AbbVie’s foothold in the global botulinum toxin arena.